KR20050014615A - Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis - Google Patents

Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis

Info

Publication number
KR20050014615A
KR20050014615A KR1020030061934A KR20030061934A KR20050014615A KR 20050014615 A KR20050014615 A KR 20050014615A KR 1020030061934 A KR1020030061934 A KR 1020030061934A KR 20030061934 A KR20030061934 A KR 20030061934A KR 20050014615 A KR20050014615 A KR 20050014615A
Authority
KR
South Korea
Prior art keywords
extract
composition
arthritis
treatment
present
Prior art date
Application number
KR1020030061934A
Other languages
Korean (ko)
Other versions
KR100542876B1 (en
Inventor
허태련
최수임
이윤미
Original Assignee
학교법인 인하학원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 학교법인 인하학원 filed Critical 학교법인 인하학원
Publication of KR20050014615A publication Critical patent/KR20050014615A/en
Application granted granted Critical
Publication of KR100542876B1 publication Critical patent/KR100542876B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/79Schisandraceae (Schisandra family)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/38Other non-alcoholic beverages
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52Adding ingredients
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/306Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00Food ingredients
    • A23V2250/20Natural extracts
    • A23V2250/21Plant extracts
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2300/00Processes
    • A23V2300/14Extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/35Extraction with lipophilic solvents, e.g. Hexane or petrol ether
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/39Complex extraction schemes, e.g. fractionation or repeated extraction steps

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PURPOSE: A composition for treatment and prevention of osteoarthritis containing Fructus schizandrae extract having an action of inhibiting hyaluronidase is provided. It inhibits hyaluronic acid decomposition by hyaluronidase in a joint generally produced in osteoarthritis patients and the inhibition of an extracellular matrix of chondrocyte cells and therefore can be used as a drug and health food for prevention and treatment of arthritis. CONSTITUTION: The composition for treatment and prevention of osteoarthritis contains Fructus schizandrae extract as an effective component. The Fructus schizandrae extract is extracted by the steps of: extracting with methanol; pouring distilled water into the methanol extract and extracting with hexane; reextracting the extraction residue with chloroform; and extracting the extraction residue with ethyl acetate. The daily dose of the composition is 1 to 100mg/kg. For an example, 100mg Fructus schizandrae extract is mixed with 100mg corn starch, 100mg lactose and 2mg magnesium stearate to give a tablet.

Description

오미자 추출물을 유효성분으로 함유하는 관절염 예방 및 치료용 조성물 {Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis}Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis

본 발명은 오미자 추출물을 유효성분으로 함유하는 관절염 예방 및 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing and treating arthritis containing Schizandra chinensis extract as an active ingredient.

관절염은 연골 관련 질환의 대표적인 것으로, 류머티스 관절염(rheumatoid arthritis)과 퇴행성 관절염(degenerative arthritis)으로 대별되며, 교통사고나 과도한 운동으로 무릎관절 연골이 손상된 경우도 흔히 발견된다. 현재, 우리나라에서 100만명 정도의 관절염 환자가 있으며, 여성이 남성보다 배이상 많고 그 중에서도 특히 갱년기 여성에게서 많이 볼 수 있는 질환이다.Arthritis is a representative of cartilage-related diseases, which are roughly classified into rheumatoid arthritis and degenerative arthritis, and knee joint cartilage is often found in traffic accidents or excessive exercise. At present, there are about one million arthritis patients in Korea, and women are more than twice as many men, especially menopausal women.

류마티스 관절염은 자가면역 질환의 일종으로, 30~50세의 여성에게 1:4의 비율로 많이 나타나며, 증상은 손가락, 팔꿈치, 무릎 등의 관절이 좌우대칭적으로 염증을 일으켜 부어서 아프고 굳어지며, 특히 새벽에 심하며 몸이 쇠약해지고 미열도 난다. 급성관절류마티스의 관절증세는 몇 일에서 몇 주 이내에 없어지는데 반하여, 류마티스 관절염은 몇 달 몇 년 동안이나 계속되다가, 관절의 변형과 탈구, 근(筋)·건(腱)의 구축(拘縮) 및 강직(强直)을 일으켜 심한 불구가 되기도 한다.Rheumatoid arthritis is a type of autoimmune disease, and it occurs in women of 30 to 50 years at a ratio of 1: 4. Symptoms include symmetrical inflammation of the joints of fingers, elbows, knees, etc. It is severe at dawn, weakness and mild fever. Arthritis of acute joint rheumatism disappears within a few days to weeks, whereas rheumatoid arthritis lasts for months and years, resulting in joint deformation, dislocation, muscle and tendon buildup. And stiffness may cause severe disability.

퇴행성 관절염은 관절 연골이 닳아 없어지면서 국소적인 퇴행성 변화가 나타나는 질환으로서, 골관절염(osteoarthritis) 또는 골관절증 이라고도 한다. 골관절염은 노령화와 밀접한 연관을 갖는 대표적인 퇴행성 질환으로, 전 인구의 10~15% 정도가 앓고 있으며, 특히 65세 이상의 고령인구 중 60~80% 정도가 골관절염을 앓고 있다.Degenerative arthritis is a disease in which local degenerative changes occur as the articular cartilage wears off. Also called osteoarthritis or osteoarthritis. Osteoarthritis is a representative degenerative disease that is closely related to aging. About 10 to 15% of the entire population suffers from osteoarthritis. In particular, about 60 to 80% of the elderly aged 65 or older suffer from osteoarthritis.

퇴행성 관절염의 원인은 노쇠 현상이나 과다한 체중과 관계가 깊으며, 나이가 많아질수록 여성에게서 더 많이 그리고 더 심하게 나타난다. 초기 증상은 한개 또는 두개의 관절이 강직과 함께 쑤시는 듯한 동통이 나타나며, 장기화 되면 관절의 변형 등을 초래하게 된다.The causes of degenerative arthritis are deeply related to senility and excessive weight, and the more and more severely in women as they age. The initial symptom is that one or two joints are swelling with stiffness, and if prolonged, the joints are deformed.

관절연골의 퇴행성 변화의 원인은 아직 규명되어 있지는 않지만, 연골세포 수의 절대적 감소와 연골세포(chondrocytes)에서 일어나는 연골기질 합성과 분해의 불균형이 하나의 원인으로 알려져 있다. 따라서, 관절연골의 퇴행성 변화는 연골기질의 분해로 인하여 연골 강도와 쿠션으로서의 능력이 감소된다.The cause of degenerative changes in articular cartilage has not yet been identified, but an absolute decrease in the number of chondrocytes and imbalances in the synthesis and degradation of chondrocytes in chondrocytes is known as one cause. Thus, degenerative changes in articular cartilage reduce cartilage strength and ability as a cushion due to degradation of cartilage substrate.

현재 임상적으로 사용되고 있는 퇴행성 관절염의 치료는 약물치료제(진통제, 스테로이드제, 비스테로이드계 항염제 등)나 연골보호제(히알루론산, 글루코사민, 콘드로이틴 등)를 이용하거나 수술적 처치(관절경 수술, 경골 근위부 절골술, 관절 부분 치환술, 슬관절 전치환술 등)에 의한다. 그러나 약물치료제의 경우는 통증이나 염증반응 자체를 비특이적으로 완화시키는 효과만을 가지며, 연골보호제는 단지 연골세포에 영양을 공급해 주거나 충격을 완화시킴으로써 관절을 보호해 주는 역할을 할 뿐이다. 또한 스테로이드성 제제는 장기간 복용 시 칼슘의 손실로 골다공증, 고혈압, 당뇨병 등을 초래 할 수 있는 부작용이 있다. 따라서 약물치료는 대부분의 경우 통증을 감소시키는 목적으로만 사용되고 있고, 영구적인 인공관절 치환술이 주를 이루고 있지만 근본적인 치료효과를 주는 약물이나 수술법은 현재까지 없는 실정이다.Currently, clinically used degenerative arthritis can be treated with medications (painkillers, steroids, nonsteroidal anti-inflammatory drugs), cartilage protectors (hyaluronic acid, glucosamine, chondroitin, etc.) or surgical treatment (arthroscopy, proximal tibia). Osteotomy, joint replacement, total knee arthroplasty, etc.). However, drug therapy has only the effect of non-specifically relieving pain or inflammatory response itself, and cartilage protection agent only serves to protect joints by nourishing chondrocytes or alleviating shock. In addition, steroidal drugs have side effects that can lead to osteoporosis, high blood pressure, diabetes, etc. due to loss of calcium when taken for a long time. Therefore, in most cases, the drug is used only for the purpose of reducing pain, and permanent arthroplasty is mainly used, but there are no drugs or surgical methods that provide a fundamental therapeutic effect.

지난 수십년 동안 퇴행성 관절염의 치료를 위해 많은 연구와 노력이 있어 왔지만, 아직 그 병리적 원인이나 근본적인 치료방법은 개발되지 않고 있다.Although much research and efforts have been made for the treatment of degenerative arthritis in the past decades, the pathological cause and the underlying treatment are not yet developed.

최근 들어 한방 치료제 및 영양보조제를 통한 관절염 치료제가 개발되고 있지만 그 치료효과와 작용기전에 관해서는 밝혀져 있지 않다. 따라서 이들 관절염 질환은 기존의 단순 대증요법제인 소염 진통제만으로는 그 질환을 효과적으로 조절하기가 어려울 뿐만 아니라 약물의 장기간 복용에 따른 부작용으로 인하여 현실적으로 환자의 대부분인 노년층에게는 치료에 많은 어려움을 초래하고 있다.Recently, the treatment of arthritis through herbal and nutritional supplements has been developed, but the therapeutic effect and mechanism of action are not known. Therefore, these arthritis diseases are not only difficult to effectively control the disease with the simple anti-inflammatory drugs, the existing simple symptomatic therapy, but also cause a lot of difficulties in the treatment of the elderly, which is the majority of patients in reality due to the side effects of long-term administration of the drug.

따라서, 관절염의 치료를 위해서는 약제를 장기간 복용할 필요가 있기 때문에, 부작용이 적은 약제의 개발이 요구되고 있다.Therefore, in order to treat arthritis, since it is necessary to take a medicament for a long time, development of a medicament with few side effects is desired.

이에 본 발명자들은 생약 추출물 중에서 히알루로니데이즈를 억제하는 물질을 연구하던 중, 오미자 추출물에서 히알루로니데이즈를 억제하는 물질이 있음을 발견하고 본 발명을 완성하였다.Accordingly, the present inventors completed the present invention while searching for a substance for inhibiting hyaluronicides among herbal extracts, and there was a substance for inhibiting hyaluronicase in Schizandra chinensis extract.

본 발명은 오미자 추출물이 히알루로니데이즈를 억제하는 작용이 있는 것을 확인하고, 이를 관절염 예방 및 치료용 의약 또는 식품에 사용하고자 하는 것이다.The present invention confirms that Schisandra chinensis extract has an action of inhibiting hyaluronides, and is intended to be used in medicine or food for preventing and treating arthritis.

도 1은 본 발명의 오미자 추출물의 추출·분리·정제방법을 나타낸 도식도이다.1 is a schematic diagram showing a method for extracting, separating and purifying Schizandra chinensis extract according to the present invention.

도 2는 본 발명의 오미자 추출물이 연골세포 콜라겐 타입 Ⅱ 발현에 미치는 영향을 나타낸 도이다.2 is a diagram showing the effect of Schizandra extract of the present invention on chondrocyte collagen type II expression.

본 발명은 오미자 추출물을 유효성분으로 함유하는 관절염 예방 및 치료용 조성물을 제공한다.The present invention provides a composition for the prevention and treatment of arthritis, containing Schizandra chinensis extract as an active ingredient.

또한, 본 발명은 오미자 추출물을 유효성분으로 함유하는 히알루로니데이즈 억제제를 제공한다.The present invention also provides a hyaluronidate inhibitor containing Schizandra chinensis extract as an active ingredient.

이하, 본 발명에 대해 상세히 설명한다.Hereinafter, the present invention will be described in detail.

오미자(五味子)의 학명은 Schizandra chinensis Baillon이며 낙엽 활엽 덩굴나무로 잎은 어긋나고 난형(卵形) 또는 도란형(倒卵形)이며 끝은 급히 뾰족하고 톱니가 있으며 뒷면 맥상에 다소 털이 있다. 꽃은 홍백색으로 6~7월에 피며 자웅이주이다. 과실은 식용으로 쓰이고 가지 끝에 이삭모양으로 늘어지며 8~9월에 붉게 익는다. 과실을 오미자(오매자), 북오미자(Schizandrae Fructus)라 한다. 표고200~1,600m 지리산, 전북, 강원도가 주산지이며 충남, 충북을 제외한 전국에 야생하고, 지리적으로 일본, 사할린, 만주, 중국에 분포한다. 과실에는 시잔드롤 (Schizandrol), 시잔드린(Schizandrin) A, B, C, 안질로일고미신(angeloylgomisin) O, P, 에피고미신(epigomisin), 프레고모이신(pregomoisin), 데옥시시잔드린 (Deoxyschizandrin) 등을 함유한다. 오미자는 오래전부터 수렴, 자양, 강장, 진해약, 해주독, 목마름, 수렴고삽, 익기생진, 보신염심 등의 약효를 가져 생약원료로 한방에서 사용해오던 재료이며, 오미자주의 원료로 오래전부터 사용되어 온 것으로서 체내 섭취에 따른 인체 안정성이 이미 확인되어 있다. 오미자 추출물은 중추신경계를 흥분시켜 강장작용과 지력활동과 노동능력을 향상시키며, 당질대사에 영향을 주어 간장 글리코겐의 이화를 촉진하여 글리코겐의 함량 증가작용, 피로회복 촉진작용, 혈압조절작용, 위액분비 조절작용이 있어 저혈압, 동맥경화, 당뇨병, 간염등에 사용되며, 항산화 효과, 항생 해독 기능, 습진 및 피부의 염증을 가라앉히는 기능, 피부노화억제, 항균, 미백 효과가 있어 화장품에도 사용되고 있다.Omija's scientific name is Schizandra chinensis Baillon, a deciduous broad-leaved vine whose leaves are alternate, ovate or obovate, with sharply pointed, jagged, somewhat hairy on the back veins. Flower is reddish white and blooms in June ~ July. Fruits are used for food and hang on the ends of branches. They ripen red in August-September. Fruits are called Schisandra (Fructus) and Schizandrae Fructus. 200 ~ 1,600m above sea level Jirisan, Jeonbuk, and Gangwon-do are the main regions, and are wild in the whole country except Chungnam and Chungbuk, and geographically distributed in Japan, Sakhalin, Manchuria, and China. Fruits include chizandrol, chizandrin A, B, C, angeloylgomisin O, P, epigomisin, pregomoisin, deoxyschizandrin ), And the like. Schisandra chinensis has long been used in herbal medicine as a raw material of medicinal herbs and has long-standing effects such as astringent, nourishment, tonic, ginhae medicine, haejudok, thirsty, astringent shovel, ripe ginjin and bosin salt. As a result, human stability has been confirmed according to the intake of the body. Schisandra chinensis extract stimulates the central nervous system, improves tonic action, intellect and labor capacity, and affects glucose metabolism to promote catabolism of hepatic glycogen, increasing glycogen content, promoting fatigue recovery, controlling blood pressure, and secreting gastric juice. It is used for low blood pressure, arteriosclerosis, diabetes, hepatitis, etc., because it has anti-oxidant effect, antibiotic detoxification function, relieves eczema and inflammation of skin, inhibits skin aging, antibacterial and whitening effect and is also used in cosmetics.

본 발명의 오미자 추출물의 제조방법은 다음과 같다.Preparation method of Schizandra chinensis extract of the present invention is as follows.

오미자를 물 또는 유기용매로 추출한다. 상기 유기용매는 알콜, 클로로포름, 헥산, 에틸아세테이트 중에서 선택하여 사용한다.Schizandra chinensis is extracted with water or organic solvent. The organic solvent is used by selecting from alcohol, chloroform, hexane, ethyl acetate.

추출방법은 상기 용매를 사용하여 냉침, 온침, 가열 등 통상의 추출방법이 가능하다.The extraction method may be a conventional extraction method such as cold needle, warm needle, heating using the solvent.

본 발명의 오미자 추출물은 뛰어난 히알루로니데이즈의 활성을 억제한다.Schizandra chinensis extract of the present invention inhibits the activity of excellent hyaluronides.

히알루론산(hyaluronic acid)은 생체 내 연골조직에 많이 함유되어 있는 물질로, 연골조직의 탄력성을 높이는데 큰 역할을 하며, 수분 함유량이 높고, 뛰어난 점탄성(viscoelasticity)을 지니고 있다.Hyaluronic acid (hyaluronic acid) is a substance that is contained in cartilage tissue in vivo, it plays a big role in increasing the elasticity of the cartilage tissue, has a high moisture content, and has excellent viscoelasticity.

이에 히알루론산의 관절강내 주입이 골관절염으로 인한 통증의 감소 및 치료 효과가 보고되어 임상학적으로도 사용되고 있다.Intraarticular injection of hyaluronic acid has been reported to reduce the pain caused by osteoarthritis and to treat it.

또한, 콜라게나제(collagenase)와 히알루로니데이즈(hyaluronidase) 등이 관절연골세포의 세포사를 증가시키고, 연골세포의 대사작용을 감소시켜 연골조직의 퇴행성 변화를 촉진한다는 연구보고가 있다.In addition, there is a research report that collagenase and hyaluronidase, etc. increase the cell death of articular chondrocytes and decrease the metabolism of chondrocytes, thereby promoting the degenerative changes of chondrocytes.

이와같이 히알루론산의 분해가 골관절염의 유발요인 또는 골관절염의 진행과정을 촉진하는 요인 중의 하나이므로, 히알루론산의 분해효소(히알루로니데이즈) 억제제는 골관절염의 예방 또는 치료제로 사용할 수 있다.Since the decomposition of hyaluronic acid is one of the factors causing osteoarthritis or the process of promoting osteoarthritis, the inhibitor of hyaluronic acid degrading enzyme (hyaluronidase) can be used as a preventive or therapeutic agent for osteoarthritis.

본 발명의 오미자 추출물은 뛰어난 히알루로니데이즈 억제 효과를 나타낸다.Schizandra chinensis extract of the present invention exhibits an excellent hyaluronatease inhibitory effect.

특히, 메탄올 추출물과 에틸아세테이트 추출물이 뛰어난 효과를 나타내었으며, n-헥산 또는 클로로포름 추출물은 히알루로니데이즈 억제 효과가 미약하다.In particular, methanol extract and ethyl acetate extract showed an excellent effect, n-hexane or chloroform extract has a weak effect of inhibiting hyaluronidase.

본 발명에서 히알루로니데이즈에 의해서 분해되어 생성되는 N-아세틸글루코사민(N-acetylglucosamine)을 DMAB(p-dimetylaminobenzaldehyde)를 이용하여 585㎚에서 비색정량 하여 측정한다.In the present invention, N-acetylglucosamine (N-acetylglucosamine) produced by decomposition by hyaluronidase is measured by colorimetric determination at 585 nm using DMAB (p-dimetylaminobenzaldehyde).

상기한 바와같이, 본 발명의 오미자 추출물은 뛰어난 히알루로니데이즈 억제 효과를 나타내는 것을 알 수 있다.As described above, it can be seen that the Schizandra chinensis extract of the present invention exhibits an excellent hyaluronidate inhibitory effect.

본 발명에서 히알루로니데이즈 억제 활성이 연골세포의 세포외기질 합성에 미치는 영향을 알아보기 위해, 연골세포에 히알루로니데이즈를 넣은 것과 연골세포에 히알루로니데이즈 및 오미자 추출물을 함께 처리한 것을 배양한 후 연골세포의 특이적인 세포외기질인 콜라겐 타입 Ⅱ의 발현량을 측정한다.In order to determine the effect of hyaluronidase inhibitory activity on the extracellular matrix synthesis of chondrocytes in the present invention, after incubating the hyaluronidase into chondrocytes and the treatment of hyaluronateides and Schisandra chinensis extract together to the chondrocytes The expression level of collagen type II, a specific extracellular matrix of chondrocytes, is measured.

상기한 바와 같이 본 발명의 오미자 추출물은, 히알루로니데이즈가 연골세포의 세포외기질 합성을 억제하는 것을 억제한다.As described above, the Schizandrae chinensis extract of the present invention inhibits hyaluronides inhibiting the extracellular matrix synthesis of chondrocytes.

본 발명의 조성물은 상기 오미자 추출물에 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다.The composition of the present invention may contain one or more active ingredients exhibiting the same or similar function in addition to the Schizandra chinensis extract.

본 발명의 조성물은 상기 오미자 추출물에 추가로 다른 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다.The composition of the present invention may contain at least one active ingredient exhibiting another function in addition to the Schizandra chinensis extract.

본 발명의 조성물은, 투여를 위해서 상기 기재한 유효성분 이외에 추가로 약제학적 또는 식품에서 허용 가능한 담체를 1종 이상 포함할 수 있다. 약제학적 또는 식품에서 허용 가능한 담체는 식염수, 멸균수, 링거액, 완충 식염수, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다. 더 나아가 당분야의 적정한 방법으로 또는 Remington's Pharmaceutical Science(최근판), Mack Publishing Company, Easton PA에 개시되어 있는 방법을 이용하여 각 질환에 따라 또는 성분에 따라 바람직하게 제제화 할 수 있다.The composition of the present invention, in addition to the above-described active ingredient for administration may further comprise one or more carriers which are acceptable in pharmaceutical or food. Pharmaceutical or food acceptable carriers may be used in combination with saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components, as necessary. And other conventional additives such as buffers and bacteriostatic agents can be added. Diluents, dispersants, surfactants, binders and lubricants may also be added in addition to formulate into injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Furthermore, it may be preferably formulated according to each disease or component by a suitable method in the art or using a method disclosed in Remington's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA.

본 발명의 조성물은 목적하는 방법에 따라 비경구 투여하거나 경구 투여할수 있으며, 경구투여가 바람직하다. 투여량은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설율 및 질환의 중증도 등에 따라 그 범위가 다양하나, 일일 투여량은 1~100㎎/㎏의 양을 일회 내지 수회에 나누어 투여하는 것이 바람직하다.The composition of the present invention can be parenterally or orally administered according to the desired method, oral administration is preferred. The dosage varies depending on the patient's weight, age, sex, health condition, diet, time of administration, method of administration, excretion rate, and severity of the disease, but the daily dosage is 1-100 mg / kg once It is preferable to administer dividedly to several times.

본 발명의 조성물은 관절염의 예방 및 치료를 위하여 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.The composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers for the prevention and treatment of arthritis.

하기에 본 발명의 조성물을 위한 제제예를 예시한다.Examples of preparations for the compositions of the present invention are illustrated below.

제제예 1Formulation Example 1 : 약학적 제제의 제조: Preparation of Pharmaceutical Formulations

1. 산제의 제조1. Preparation of powder

오미자 추출물 에틸아세테이트 분획 2gSchisandra chinensis extract ethyl acetate fraction 2g

유당 1g1g lactose

상기의 성분을 혼합하고 기밀포에 충진하여 산제를 제조하였다.The above ingredients were mixed and filled in airtight cloth to prepare a powder.

2. 정제의 제조2. Preparation of Tablets

오미자 추출물 에틸아세테이트 분획 100㎎Schizandra chinensis extract ethyl acetate fraction 100mg

옥수수전분 100㎎Corn Starch 100mg

유 당 100㎎Lactose 100mg

스테아린산 마그네슘 2㎎2 mg magnesium stearate

상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

3. 캡슐제의 제조3. Preparation of Capsule

오미자 추출물 에틸아세테이트 분획 100㎎Schizandra chinensis extract ethyl acetate fraction 100mg

옥수수전분 100㎎Corn Starch 100mg

유 당 100㎎Lactose 100mg

스테아린산 마그네슘 2㎎2 mg magnesium stearate

상기의 성분을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.After mixing the above components, the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.

본 발명의 조성물은 관절염에 기인하는 질환의 개선을 목적으로 식품 또는 음료에 첨가될 수 있다. 이 때 첨가하는 양은 건강식품 조성물일 경우 전체 식품 중량의 1~5 중량%, 바람직하게는 3 중량%로 가할 수 있으며, 건강음료 조성물일 경우 100㎖를 기준으로 1~3g, 바람직하게는 2g의 비율로 가할 수 있다.The compositions of the present invention may be added to foods or beverages for the purpose of ameliorating diseases caused by arthritis. In this case, the amount added may be added in an amount of 1 to 5% by weight, preferably 3% by weight of the total food weight in the case of the health food composition, and in the case of the health beverage composition, 1 to 3g, preferably 2g Can be added in proportion.

본 발명의 건강음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나,사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100㎖당 일반적으로 약 2~5g, 바람직하게는 약 4g 이다.The health beverage composition of the present invention may contain various flavors or natural carbohydrates, etc. as additional components, as in the general beverage. The above-mentioned natural carbohydrates are glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol and erythritol. As the sweetener, natural sweeteners such as tautin and stevia extract, synthetic sweeteners such as saccharin, aspartame, and the like can be used. The proportion of the natural carbohydrate is generally about 2-5 g, preferably about 4 g per 100 ml of the composition of the present invention.

상기 외에 본 발명의 조성물은 여러가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 조성물은 천연 과일쥬스, 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부 당 1~5 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the composition of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonic acid. Carbonating agents and the like used in beverages. In addition, the composition of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The proportion of such additives is not critical but is usually selected in the range of 1 to 5 parts by weight per 100 parts by weight of the composition of the present invention.

제제예 2Formulation Example 2 : 식품의 제조: Manufacture of food

본 발명의 오미자 추출물을 포함하는 식품들을 다음과 같이 제조하였다.Foods containing the Schisandra chinensis extract of the present invention were prepared as follows.

1. 조리용 양념의 제조1. Preparation of Cooking Seasonings

본 발명의 오미자 추출물 20 ~ 95 중량%로 건강 증진용 조리용 양념을 제조하였다.Schisandra chinensis extract of the present invention was prepared in 20 to 95% by weight for health promotion cooking seasoning.

2. 토마토 케찹 및 소스의 제조2. Preparation of Tomato Ketchup and Sauce

본 발명의 오미자 추출물 0.2 ~ 1.0 중량%를 토마토 케찹 또는 소스에 첨가하여 건강 증진용 토마토 케찹 또는 소스를 제조하였다.0.2 ~ 1.0% by weight of Schizandra extract of the present invention was added to tomato ketchup or sauce to prepare tomato ketchup or sauce for health promotion.

3. 밀가루 식품의 제조3. Manufacturing of Flour Foods

본 발명의 오미자 추출물 0.5 ~ 5.0 중량%를 밀가루에 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강 증진용 식품을 제조하였다.0.5 ~ 5.0% by weight of Schizandra chinensis extract of the present invention was added to the flour, and using the mixture to prepare bread, cakes, cookies, crackers and noodles to prepare foods for health promotion.

4. 스프 및 육즙(gravies)의 제조4. Preparation of soups and gravy

본 발명의 오미자 추출물 0.1 ~ 5.0 중량%를 스프 및 육즙에 첨가하여 건강 증진용 육가공 제품, 면류의 수프 및 육즙을 제조하였다.0.1-5.0 wt% of Schizandra chinensis extract of the present invention was added to soups and broths to prepare meat products for health promotion, soups and noodles for noodles.

5. 그라운드 비프(ground beef)의 제조5. Preparation of Ground Beef

본 발명의 오미자 추출물 10 중량%를 그라운드 비프에 첨가하여 건강 증진용 그라운드 비프를 제조하였다.10 wt% of Schisandra chinensis extract of the present invention was added to ground beef to prepare a ground beef for health promotion.

6. 유제품(dairy products)의 제조6. Manufacture of Dairy Products

본 발명의 오미자 추출물 5 ~ 10 중량%를 우유에 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.5 to 10% by weight of Schizandra chinensis extract of the present invention was added to milk, and the milk was used to prepare various dairy products such as butter and ice cream.

7. 선식의 제조7. Manufacture of wire

현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60메쉬의 분말로 제조하였다.Brown rice, barley, glutinous rice, and yulmu were alphad by a known method, and then dried and roasted to prepare a powder having a particle size of 60 mesh using a grinder.

검정콩, 검정깨, 들깨도 공지의 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60메쉬의 분말로 제조하였다.Black beans, black sesame seeds, and perilla were also steamed and dried by a known method, and then ground to a powder having a particle size of 60 mesh.

본 발명의 오미자 추출물을 진공 농축기에서 감압·농축하고, 분무, 열풍건조기로 건조하여 얻은 건조물을 분쇄기로 입도 60메쉬로 분쇄하여 건조분말을 얻었다.The Schizandra chinensis extract of the present invention was decompressed and concentrated in a vacuum concentrator, and the dried product obtained by drying with a sprayer or a hot air dryer was pulverized with a particle size of 60 mesh to obtain a dry powder.

상기에서 제조한 곡물류, 종실류 및 오미자 추출물의 건조분말을 다음의 비율로 배합하여 제조하였다.It was prepared by combining the dry powder of the grains, seeds and Schisandra chinensis extract prepared in the following ratio.

곡물류(현미 30중량%, 율무 15중량%, 보리 20중량%),Cereals (30% by weight brown rice, 15% by weight radish, 20% by weight barley),

종실류(들깨 7중량%, 검정콩 8중량%, 검정깨 7중량%),Seeds (7% by weight perilla, 8% by weight black beans, 7% by weight black sesame),

오미자 추출물의 건조분말(3 중량%),Dry powder of Schizandra chinensis extract (3% by weight),

영지(0.5중량%),Ganoderma lucidum (0.5% by weight),

지황(0.5중량%)Foxglove (0.5 wt%)

제제예 3Formulation Example 3 : 음료의 제조: Preparation of Beverages

1. 탄산음료의 제조1. Preparation of Carbonated Drinks

설탕 5~10%, 구연산 0.05~0.3%, 카라멜 0.005~0.02%, 비타민 C 0.1~1%의 첨가물을 혼합하고, 여기에 79~94%의 정제수를 섞어서 시럽을 만들고, 상기 시럽을 85~98℃에서 20~180초간 살균하여 냉각수와 1:4의 비율로 혼합한 다음 탄산가스를0.5~0.82%를 주입하여 본 발명의 오미자 추출물을 함유하는 탄산음료를 제조하였다.5-10% of sugar, 0.05-0.3% citric acid, 0.005-0.02% caramel, 0.1-1% of vitamin C are mixed, and 79-94% purified water is mixed to make syrup, and the syrup is 85-98 Sterilizing at 20 ℃ for 180 seconds to mix with a cooling water 1: 1: ratio of carbon dioxide gas was injected 0.5 ~ 0.82% to prepare a carbonated beverage containing Schizandra extract of the present invention.

2. 건강음료의 제조2. Manufacture of health drinks

액상과당(0.5%), 올리고당(2%), 설탕(2%), 식염(0.5%), 물(75%)과 같은 부재료와 오미자 추출물을 균질하게 배합하여 순간 살균을 한 후 이를 유리병, 패트병 등 소포장 용기에 포장하여 건강음료를 제조하였다.Instant sterilization by homogeneously mixing minor ingredients such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%), water (75%) and Schizandra chinensis extract Health drinks were prepared by packaging in small packaging containers such as plastic bottles.

3. 야채쥬스의 제조3. Preparation of Vegetable Juice

본 발명의 오미자 추출물 5g을 토마토 또는 당근 쥬스 1,000㎖에 가하여 건강 증진용 야채쥬스를 제조하였다.5 g of Schisandra chinensis extract of the present invention was added to 1,000 ml of tomato or carrot juice to prepare a vegetable juice for health promotion.

4. 과일쥬스의 제조4. Preparation of Fruit Juice

본 발명의 오미자 추출물 1g을 사과 또는 포도 쥬스 1,000㎖에 가하여 건강 증진용 과일쥬스를 제조하였다.1 g of Schizandra chinensis extract of the present invention was added to 1,000 ml of apple or grape juice to prepare fruit juice for health promotion.

이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시한다. 그러나 하기의 실시예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 실시예에 의해 본 발명의 내용이 한정되는 것은 아니다.Hereinafter, preferred examples are provided to aid in understanding the present invention. However, the following examples are merely provided to more easily understand the present invention, and the contents of the present invention are not limited by the examples.

실시예 1Example 1 : 오미자 추출물의 제조: Preparation of Schizandra chinensis Extract

1. 오미자 조추출물1.Schisandra chinensis extract

1) 오미자 물 추출물1) Schizandra Water Extract

건조한 오미자 열매 3㎏을 세절 한 후, 물로 24시간씩 5회 반복하여 교반 추출한 다음 여과지에 여과한 후 여액을 감압농축하여 물 추출물을 얻었다.After cutting 3 kg of dried Schisandra chinensis fruits, stirring and extracting was repeated five times for 24 hours each with water, and then filtered through a filter paper, and the filtrate was concentrated under reduced pressure to obtain a water extract.

2) 오미자 유기용매 추출물2) Schizandra Organic Solvent Extract

건조한 오미자 열매 3㎏을 세절 한 후, 메탄올로 24시간씩 5회 반복하여 교반 추출한 다음 여과지에 여과한 후 여액을 감압농축하여 메탄올 추출물을 얻었다.After cutting 3 kg of dried Schisandra chinensis fruit, the mixture was extracted by stirring repeatedly for 5 hours with methanol for 24 hours, filtered through a filter paper, and the filtrate was concentrated under reduced pressure to obtain a methanol extract.

2. 오미자 추출물의 분리2. Isolation of Schizandra chinensis Extract

상기 1의 2)에서 얻어진 메탄올 추출물에 증류수를 넣은 후 헥산으로 추출하고, 그 추출잔사를 클로로포름으로 재추출 한 후, 그 추출잔사를 다시 에틸아세테이트로 추출하였다.Distilled water was added to the methanol extract obtained in 2) and extracted with hexane. The extracted residue was reextracted with chloroform, and the extracted residue was extracted with ethyl acetate again.

상기 에틸아세테이트 추출물을 TLC(Thin Layer Chromatography)를 이용하여 활성물질의 수를 확인하고, 실리카(silica), C18및 NH2크로마토그래피 컬럼을 이용하여 활성분획을 정제하였다.The ethyl acetate extract was checked for the number of active substances using TLC (Thin Layer Chromatography), and the active fractions were purified using silica, C 18 and NH 2 chromatography columns.

본 발명의 오미자 추출물의 추출·분리·정제방법은 도 1에 나타내었다.Extraction, separation and purification of the Schizandra chinensis extract of the present invention is shown in FIG.

실험예 1Experimental Example 1 : 오미자 추출물의 히알루로니데이즈 활성 억제도 측정: Determination of Hyaluronidase Activity of Schizandra chinensis Extract

본 발명의 오미자 추출물의 히알루로니데이즈의 활성 억제도를 알아보기 위하여 Morgan-Elson Assay 법을 이용하여 활성을 측정하였다.In order to determine the inhibitory activity of hyaluronides of the Schizandra chinensis extract of the present invention, the activity was measured using the Morgan-Elson Assay method.

인산완충용액에 녹인 히알루론산과 DMSO에 녹인 오미자 추출물을 각각 넣고 37℃에서 20분간 배양하였다. 배양한 후에 화합물 48/80용액을 넣고 2차 배양하였다. 히알루론산을 넣고 3차 배양 한 후 K3BO3를 넣고 열탕에서 가열하여 반응을 중지시켰다. 원심분리 후, 히알루론산이 히알루로니데이즈에 의해서 분해되어 생성되는 N-알세틸글루코사민(N-acetylglucosamine)을 DMAB(p-dimetylaminobenzaldehyde)를 이용하여 585㎚에서 비색정량 하여 활성을 검증하였다.Hyaluronic acid dissolved in phosphate buffer solution and Schizandra chinensis extract dissolved in DMSO, respectively, were added and incubated at 37 ° C. for 20 minutes. After incubation, the compound 48/80 solution was added and then secondary cultured. After hyaluronic acid was added and tertiary incubation, K 3 BO 3 was added thereto, and the reaction was stopped by heating in a boiling water. After centrifugation, N-acetylglucosamine (N-acetylglucosamine) produced by the decomposition of hyaluronic acid by hyaluronates was verified by colorimetric determination at 585 nm using DMAB (p-dimetylaminobenzaldehyde).

결과는 표 1에 나타내었다.The results are shown in Table 1.

오미자 추출물 분획의 히알루로니데이즈 활성 억제도Inhibition of Hyaluronidase Activity of Schisandra chinensis Fractions 메탄올 추출물Methanol extract n-헥산가용성 분획n-hexanesoluble fraction 클로로포름가용성 분획Chloroform Soluble Fraction 에틸아세테이트가용성 분획Ethyl Acetate Soluble Fraction 활성 억제도(%)% Activity inhibition 62.6±0.7162.6 ± 0.71 10.0±0.2810.0 ± 0.28 2.6±0.072.6 ± 0.07 59.0±2.7959.0 ± 2.79

표 1에 나타난 바와 같이, 본 발명의 오미자 추출물은 히알루로니데이즈의 활성을 현저히 억제함을 알 수 있다.As shown in Table 1, Schizandra extract of the present invention can be seen that significantly inhibit the activity of hyaluronidase.

실험예 2Experimental Example 2 : 오미자 추출물이 관절연골세포(C28/I2 cell) 증식 및 세포외기질 합성에 미치는 영향: Effect of Schizandra chinensis Extract on the Growth of Articular Chondrocytes (C28 / I2 Cells) and Extracellular Matrix Synthesis

본 발명의 오미자 추출물의 Human costal 연골세포에 대한 히알루로니데이즈 효소 저해 활성과 연골세포의 세포외기질 합성에 미치는 영향을 알아보기 위하여, 연골의 특이적인 세포외기질인 콜라겐 타입 Ⅱ의 발현양상을 RT-PCR을 통해 확인하였다.In order to investigate the effects of the hyaluronatease enzyme inhibitory activity and the extracellular matrix synthesis of chondrocytes on the human costal chondrocytes of Schizandra chinensis extract, the expression pattern of collagen type II, which is a specific extracellular matrix of cartilage, was determined by RT. -Confirmed by PCR.

Human costal 연골세포가 배양된 접시에 각각 1) 대조군(연골세포), 2) 히알루로니데이즈 처리군, 3) 오미자 추출물과 히알루로니데이즈 처리군으로, 처리한 후 24~72 시간 관찰하였다.Human costal chondrocytes were cultured in 1) control group (chondrocytes), 2) hyaluronidase treated group, 3) Schizandra extract and hyaluronidase treated groups, and observed for 24 ~ 72 hours.

단층 배양된 연골세포를 떼어낸 후 총 RNA는 Trizol Reagent(RNA extraction Kit, GIBCOBRL)를 이용하여 분리하였다. 각각의 군에 대하여 동량의 RNA를 AMV 역전사효소(BMS)를 이용하여 complementary DNA(cDNA)를 만든 뒤, 이를 템플레이트 (template)로 하여 콜라겐 타입 Ⅱ와 GAPDH에 대한 각각의 프라이머를 제작하여 PCR로 증폭시킨 후 아가로즈겔에 전기영동하여 변화를 확인하였다.After removing monolayer cultured chondrocytes, total RNA was isolated using Trizol Reagent (RNA extraction Kit, GIBCOBRL). Complementary DNA (cDNA) was prepared using AMV reverse transcriptase (BMS) for the same amount of RNA for each group, which was then amplified by PCR using primers for collagen type II and GAPDH. After the change was confirmed by electrophoresis on the agarose gel.

결과는 도2에 나타내었다.The results are shown in FIG.

도 2에 나타난 바와 같이, 본 발명의 오미자 추출물을 처리하면 히알루로니데이즈 단독 처리군 보다 콜라게 발현이 증대된 것을 알 수 있으며, 이는 오미자 추출물이 히알루로니데이즈가 연골세포의 세포외기질 합성을 억제하는 것을 다시 억제하는 것을 알 수 있다.As shown in Figure 2, the treatment of the Schizandra chinensis extract of the present invention can be seen that the collagen expression is increased than the hyaluronidase alone treatment group, which is that Schizandra extract inhibits the synthesis of extracellular matrix of chondrocytes. It can be seen that it suppresses again.

따라서, 본 발명의 오미자 추출물이 히아루로니데이즈의 활성을 억제함을 알 수 있다.Therefore, it can be seen that the Schizandra chinensis extract of the present invention inhibits the activity of hyaluronides.

본 발명의 오미자 추출물을 유효성분으로 함유하는 조성물은, 골관절염 환자에게서 일반적으로 발생되는 관절내의 히알루로니데이즈에 의한 히알루론산 분해를 탁월하게 억제하고 히알루로니데이즈가 연골세포의 세포외기질 합성을 억제하는 것을 억제함으로서, 관절염의 예방 및 치료를 위한 의약 및 건강식품에 유용하게 사용될 수 있다.The composition containing the Schizandra chinensis extract of the present invention as an active ingredient is excellent in inhibiting hyaluronic acid degradation by hyaluronic acid in the joints commonly occurring in osteoarthritis patients, and hyaluronicase inhibits the extracellular matrix synthesis of chondrocytes. It can be usefully used in medicine and health foods for the prevention and treatment of arthritis by suppressing that.

Claims (7)

오미자 추출물을 유효성분으로 함유하는 관절염 예방 및 치료용 조성물.Arthritis prevention and treatment composition containing Schizandra chinensis extract as an active ingredient. 제 1항에 있어서, 오미자 추출물은 물 또는 유기용매로 추출하는 것을 특징으로 하는 관절염 예방 및 치료용 조성물.According to claim 1, Schisandra chinensis extract is a composition for preventing and treating arthritis, characterized in that the extraction with water or an organic solvent. 제 2항에 있어서, 상기 유기용매는 알콜, 클로로포름, 헥산, 에틸아세테이트 중에서 선택된 것을 특징으로 하는 관절염 예방 및 치료용 조성물.The method of claim 2, wherein the organic solvent is a composition for preventing and treating arthritis, characterized in that selected from alcohol, chloroform, hexane, ethyl acetate. 제 1항에 있어서, 상기 오미자 추출물은 오미자를 메탄올로 추출하고, 상기 메탄올 추출물에 증류수를 넣은 후 헥산으로 추출하고, 그 추출잔사를 클로로포름으로 재추출 한 후, 그 추출잔사를 다시 에틸아세테이트로 추출하는 것을 특징으로 하는 관절염 예방 및 치료용 조성물.The extract of Schizandra chinensis extract according to claim 1, wherein Schizandra chinensis extract is extracted with methanol, distilled water is added to the methanol extract, and then extracted with hexane. Arthritis prevention and treatment composition, characterized in that. 제 1항 내지 제 4항 중 어느 한 항의 조성물을 함유하는 관절염 예방 및 치료용 약학 조성물.A pharmaceutical composition for the prevention and treatment of arthritis, comprising the composition of any one of claims 1 to 4. 제 1항 내지 제 4항 중 어느 한 항의 조성물을 함유하는 관절염 예방 및 치료용 식품 조성물.Food composition for the prevention and treatment of arthritis, containing the composition of any one of claims 1 to 4. 오미자 추출물을 유효성분으로 함유하는 히알루로니데이즈 억제제.Hyaluronidase inhibitor containing Schizandra chinensis extract as an active ingredient.
KR1020030061934A 2003-07-30 2003-09-04 Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis KR100542876B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020030052875 2003-07-30
KR20030052875 2003-07-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020050115865A Division KR100597235B1 (en) 2003-07-30 2005-11-30 Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis

Publications (2)

Publication Number Publication Date
KR20050014615A true KR20050014615A (en) 2005-02-07
KR100542876B1 KR100542876B1 (en) 2006-01-20

Family

ID=37104931

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020030061934A KR100542876B1 (en) 2003-07-30 2003-09-04 Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis
KR1020050115865A KR100597235B1 (en) 2003-07-30 2005-11-30 Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020050115865A KR100597235B1 (en) 2003-07-30 2005-11-30 Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis

Country Status (1)

Country Link
KR (2) KR100542876B1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011019153A2 (en) * 2009-08-12 2011-02-17 (주) 와이디생명과학 Composition for preventing or treating arthritis, containing an extract of an herbal medicine mixture of schisandra chinensis baillon, scutellaria baicalensis and kalopanax pictus nakai as an active ingredient
KR20180044772A (en) * 2016-10-24 2018-05-03 주식회사 바이오포트코리아 Maximowiczia Chinensis Extracts effective component for preventing and treating arthritis And Manufacturing Method of thereof
KR20190036903A (en) 2017-09-28 2019-04-05 (주)휴럼 Litsenolide used as an active ingredient for prevention and treatment of inflammation and osteoarthritis, and A composition comprising the same as an active ingredient
WO2019177327A1 (en) * 2018-03-12 2019-09-19 한국 한의학 연구원 Composition comprising schisandra chinensis extract as effective ingredient for prevention, alleviation, or treatment of arthritis

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100930910B1 (en) 2007-10-10 2009-12-10 문경시 Beverage containing fresh Schisandra chinensis liquid and its manufacturing method
WO2012045400A1 (en) * 2010-10-05 2012-04-12 Cognis Ip Management Gmbh An extract of the fruit of the plant schisandra chinensis
KR20150115414A (en) * 2014-04-04 2015-10-14 한국생명공학연구원 The pharmaceutical compositions for prevention or treatment of inflammatory diseases or promotion of wound healing containing ethylacetate fraction of Schizandra chinensis Baillon
KR20240131530A (en) 2023-02-23 2024-09-02 동의과학대학교산학협력단 A health drink composition containing herbal extracts with excellent muscle and bone strengthening effects as active ingredients

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011019153A2 (en) * 2009-08-12 2011-02-17 (주) 와이디생명과학 Composition for preventing or treating arthritis, containing an extract of an herbal medicine mixture of schisandra chinensis baillon, scutellaria baicalensis and kalopanax pictus nakai as an active ingredient
WO2011019153A3 (en) * 2009-08-12 2011-03-31 (주) 와이디생명과학 Composition for preventing or treating arthritis, containing an extract of an herbal medicine mixture of schisandra chinensis baillon, scutellaria baicalensis and kalopanax pictus nakai as an active ingredient
KR20180044772A (en) * 2016-10-24 2018-05-03 주식회사 바이오포트코리아 Maximowiczia Chinensis Extracts effective component for preventing and treating arthritis And Manufacturing Method of thereof
KR20190036903A (en) 2017-09-28 2019-04-05 (주)휴럼 Litsenolide used as an active ingredient for prevention and treatment of inflammation and osteoarthritis, and A composition comprising the same as an active ingredient
WO2019177327A1 (en) * 2018-03-12 2019-09-19 한국 한의학 연구원 Composition comprising schisandra chinensis extract as effective ingredient for prevention, alleviation, or treatment of arthritis

Also Published As

Publication number Publication date
KR100597235B1 (en) 2006-07-06
KR20060001877A (en) 2006-01-06
KR100542876B1 (en) 2006-01-20

Similar Documents

Publication Publication Date Title
KR100597235B1 (en) Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis
KR100589050B1 (en) Composition comprising Astragali Radix extract and isoflavonoid compound isolated from the same as an effective component for preventing and treating arthritis
KR100626358B1 (en) Herbal mixture extract of Notoginseng Radix, Rehmanniae Radix Preparata and Acanthopanacis Cortex and composition comprising the same for prevention and treatment of arthritis
JP4496127B2 (en) Herbal extract mixture and preventive or therapeutic agent for osteoporosis
KR101018403B1 (en) composition comprising the extract of soybean leaves for the prevention?delay or treatment of gout
KR20050114929A (en) Composition for treating and preventing constipation
KR100874778B1 (en) Composition for the prevention and treatment of menopausal diseases comprising fermented Cheonggukjang extract
KR101525877B1 (en) A composition for preventing wrinkle of skin and anti aging of skin
KR101910013B1 (en) A composition for improving, preventing and treating of pain comprising herb extract
KR101899555B1 (en) A composition for improving, preventing and treating arthritis comprising Stewartia koreana extract and Rhus verniciflua stokes extract
KR100680628B1 (en) A herbal mixture extract of Rehmanniae Radix Preparata and Acanthopanacis Cortex and composition comprising the same for prevention and treatment of osteoporosis
KR101023487B1 (en) Arthritis prevention or treatment composition comprising a mixed herbal extract of Schisandra chinensis, golden and thawed skin as an active ingredient
KR20200014566A (en) A composition for improving, preventing and treating of arthritis comprising Milk thistle and Achyranthes bidentata Blume
KR20100009151A (en) Composition containing mixture extract of saururus chinesis and scutellaria baicalensis for prevention or treatment of osteoporosis
KR100656571B1 (en) Composition for preventation and treatment of degenerative arthritis
KR20220000185A (en) A pharmaceutical composition for the prevention or treatment of arthritis comprising peony and licorice mixed extract
KR20110051545A (en) Composition for preventing or treating gout comprising mulberry fermentation extract
KR100538983B1 (en) Pharmaceutical composition comprising the crude drug extract for improving liver function
KR102545762B1 (en) Composition for preventing or treating osteoarthritis comprising Gloiopeltis tenax estract
KR102448274B1 (en) Composition for preventing, ameliorating or treating bone disease comprising crude polysaccharide fraction of Psoralea corylifolia extract as effective component
KR101904819B1 (en) Composition comprising Fermented Momordica charantia L. and Allium sativum L. using Amyloliquefaciens Bacillus Jis-1 for lowering blood glucose or preventing and treating diabetes mellitus
KR20230161338A (en) Composition for prevention, improvement or treatment of arthritis and joint pain comprising Spiraea prunifolia var. simpliciflora extract as effective component
KR20230161341A (en) Composition for prevention, improvement or treatment of arthritis and joint pain comprising Lysimachia mauritiana extract as effective component
KR20230161337A (en) Composition for prevention, improvement or treatment of arthritis comprising Lysimachia japonica extract as effective component
KR20230161339A (en) Composition for prevention, improvement or treatment of arthritis and joint pain comprising Ribes fasciculatum var. chinense extract as effective component

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
A107 Divisional application of patent
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130103

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20131217

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20141204

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20160104

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20161220

Year of fee payment: 12

FPAY Annual fee payment

Payment date: 20171213

Year of fee payment: 13

FPAY Annual fee payment

Payment date: 20181226

Year of fee payment: 14

FPAY Annual fee payment

Payment date: 20200102

Year of fee payment: 15